Table 14.
CXCL12-CXCR4 axis blockade for cancer therapy
| Target | Products | NCT number | Cancer types | Combination partners | Phase | Status |
|---|---|---|---|---|---|---|
| CXCL12 | Olaptesed | NCT03168139 | Colorectal and Pancreatic Cancer | Pembrolizumab | I/II | Completed |
| NCT04901741 | Pancreatic Cancer | Pembrolizumab and Chemotherapy | II | Not yet recruiting | ||
| NCT04121455 | Glioblastoma | Radiotherapy and Bevacizumab/Pembrolizumab | I/II | Active, not recruiting | ||
| NCT01486797 | Chronic Lymphocytic Leukemia | Bendamustine and Rituximab | II | Completed | ||
| CXCR4 | Plerixafor | NCT04177810 | Pancreatic Cancer | Cemiplimab | II | Completed |
| NCT00914849 | Hematologic Neoplasms | Monotherapy | II | Completed | ||
| NCT04058145 | Head and Neck Cancer | Pembrolizumab | II | Withdrawn | ||
| NCT02179970 | Pancreatic, Ovarian and Colorectal Cancers | Monotherapy | I | Completed | ||
| NCT01753453 | MM | G-CSF | II | Completed | ||
| NCT03277209 | Pancreatic Cancer | Monotherapy | I | Terminated | ||
| NCT01288573 | Pediatric Cancer | Monotherapy | I/II | Completed | ||
| NCT00241358 | Hematological Malignancies | Monotherapy | I/II | Completed | ||
| NCT01225419 | Pediatric Cancer | Monotherapy | II | Completed | ||
| MSX-122 | NCT00591682 | Solid Tumors | Monotherapy | I | Suspended | |
| BL-8040 | NCT02907099 | Pancreatic Cancer | Pembrolizumab | II | Completed | |
| NCT02826486 | Pancreatic Cancer | Pembrolizumab and Onivyde | II | Completed | ||
| NCT02639559 | Hematological Malignancies | Monotherapy | II | Completed | ||
| NCT04543071 | Pancreatic Cancer | Cemiplimab, Gemcitabine, and Nab-Paclitaxel | II | Recruiting | ||
| NCT03246529 | MM | G-CSF | III | Active, not recruiting | ||
| NCT03281369 | Gastric or Gastroesophageal Junction or Esophageal Cancer | Atezolizumab | I/II | Active, not recruiting | ||
| NCT03193190 | Pancreatic Cancer | Atezolizumab | I/II | Active, not recruiting | ||
| NCT01838395 | Acute Myeloid Leukemia | Ara-C | II | Completed | ||
| NCT03154827 | Acute Myeloid Leukemia | Atezolizumab | I/II | Terminated | ||
| NCT02763384 | T-Acute Lymphoblastic Leukemia | Nelarabine | II | Terminated | ||
| NCT02115672 | Chronic Myeloid Leukemia | Imatinib | I/II | Withdrawn | ||
| LY2510924 | NCT02737072 | Solid Tumor | Durvalumab | I | Terminated | |
| NCT01439568 | Extensive Stage Small Cell Lung Carcinoma | Carboplatin and Etoposide | II | Completed | ||
| NCT01391130 | ccRCC | Sunitinib | II | Terminated | ||
| NCT02652871 | Leukemia | Idarubicin and Cytarabine | I | Completed |
Note: ccRCC clear cell renal cell carcinoma, SCLC small cell lung carcinoma, MM multiple myeloma